Purpose: We explored the mechanism effects of “The Same Treatment for Different metabolic Diseases” concept in traditional Chinese medicine (TCM).Methods: Network pharmacology, molecular docking technology and KATZ score were employed to predict the targets and signaling pathways affected by Shugan Quzhi Capsules (SGQZ), which are used to treat obesity, hyperlipidemia, and non-alcoholic fatty liver disease.Results: A total of 492 active ingredients in SGQZ were found to act on 666 potential targets. They were involved in GO biological processes related to lipid metabolism, oxidative stress, anti-inflammatory effects, and calcium ion channel effects; the three most significantly enriched KEGG pathways were endocrine resistance, advanced glycation end-product (AGE)/receptor for AGEs signaling pathway in diabetic complications, and peroxisome proliferator-activated receptor (PPAR) signaling. The correlation between SGQZ and each metabolic disease was ranked as NAFLD>hyperlipidemia>obesity.Conclusions: Our results clarify the mechanisms of action of SGQZ on three conditions, demonstrating the utility of “The Same Treatment for metabolic Different Diseases” from both the target and pathway perspectives. Among them, leptin, apolipoprotein B, and PPARG and PPAR-/AMP-activated protein kinase-related signal pathways are the key targets and pathways for SGQZ. In TCM terminology, the spleen and liver meridians are the key routes by which quercetin and apigenin in SGQZ exert their effects.